Advaxis advances clinical development of prostate cancer vaccine

Advaxis, Inc., a biotechnology company that develops proprietary, live, attenuated Listeria monocytogenes immunotherapeutics that deliver engineered tumor antigens, which are used to fight cancer, announced that it is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials, according to BusinessWire.

Advaxis is working with Dr. Chandan Guha at the Albert Einstein College of Medicine and Montefiore Medical Center to develop ADXS31-142 in human trials, BusinessWire states. The company plans to conduct a Phase 1 study with Dr. Guha after manufacturing trials are completed.

"Prostate cancer is an excellent target for immunotherapy," Dr. John Rothman, Executive VP of Science and Operations said, according to BusinessWire. 

The company's prostate cancer vaccine is designed to attack and kill cells that secrete prostate specific antigen, according to BusinessWire. It is Advaxis' answer to a federally approved treatment created by another industry leader.

"The approval of Dendreon Corporation's Provenge by the Food and Drug Administration (FDA) is an exciting development in the study of cancer immunotherapy. Our collaboration with Dr. Guha, coupled with our recent success in raising funds and some very promising new preclinical research has led us to commit to moving forward immediately on a prostate program with our proprietary live Listeria technology platform," Advaxis Chairman/CEO Thomas A. Moore said, according to BusinessWire. "If human results approach our animal results, we may be able to offer an immunotherapy that is less expensive, more effective and suitable for use prior to the induction of chemical castration of prostate cancer patients."